Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
![GlobeNewswire](../../../Content/images/providers/GN.png)
Centessa Pharmaceuticals plc - American Depositary Shares (CNTA)
Company Research
Source: GlobeNewswire
Tokyo, Japan and Cambridge, UK, 30 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) today announced that it expects to receive $4.6 million in milestone payments from Centessa Pharmaceuticals pursuant to a license agreement regarding Nxera technology used to help design Centessa’s novel orexin receptor 2 (OX2R) agonist, ORX750. The milestone was achieved with clearance of the ORX750 Investigational New Drug application and progression of ORX750 into a Phase 1 clinical trial. ORX750 is an investigational, orally administered, highly potent and selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 (NT1), with potential applicability to narcolepsy type 2 (NT2), idiopathic hypersomnia, and other sleep-wake disorders with normal orexin levels. –END– About Nxera PharmaNxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the li
Show less
Read more
Impact Snapshot
Event Time:
CNTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTA alerts
High impacting Centessa Pharmaceuticals plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CNTA
News
- Centessa Pharmaceuticals plc (NASDAQ: CNTA) had its price target raised by analysts at Morgan Stanley from $8.00 to $11.00. They now have an "equal weight" rating on the stock.MarketBeat
- Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer [Yahoo! Finance]Yahoo! Finance
- Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business OfficerGlobeNewswire
- Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
- Centessa Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire
CNTA
Earnings
- 5/13/24 - Beat
CNTA
Sec Filings
- 6/17/24 - Form 3
- 6/10/24 - Form 8-K
- 5/21/24 - Form DEFA14A
- CNTA's page on the SEC website